Bath Savings Trust Co Sells 5,777 Shares of Danaher Corporation $DHR

Bath Savings Trust Co lessened its stake in shares of Danaher Corporation (NYSE:DHR) by 8.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 59,099 shares of the conglomerate’s stock after selling 5,777 shares during the period. Danaher accounts for about 1.2% of Bath Savings Trust Co’s portfolio, making the stock its 26th largest position. Bath Savings Trust Co’s holdings in Danaher were worth $11,717,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also added to or reduced their stakes in DHR. WFA of San Diego LLC bought a new position in shares of Danaher in the 2nd quarter worth $26,000. Howard Hughes Medical Institute bought a new position in shares of Danaher in the second quarter valued at approximately $27,000. Red Tortoise LLC increased its position in shares of Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after purchasing an additional 98 shares during the last quarter. Heartwood Wealth Advisors LLC purchased a new stake in Danaher during the third quarter worth about $37,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Danaher in the second quarter valued at $40,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

Shares of DHR stock opened at $224.43 on Friday. The stock has a market cap of $158.53 billion, a PE ratio of 46.28, a price-to-earnings-growth ratio of 4.32 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $258.23. The company’s fifty day moving average price is $219.93 and its 200-day moving average price is $206.66.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period last year, the business earned $1.71 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. On average, equities analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s payout ratio is 26.39%.

Insider Activity at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This trade represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 30,248 shares of company stock valued at $6,609,663. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Robert W. Baird set a $247.00 price target on Danaher in a report on Wednesday, October 22nd. The Goldman Sachs Group began coverage on shares of Danaher in a research report on Tuesday, December 9th. They set a “buy” rating and a $265.00 price objective on the stock. HSBC upped their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, December 1st. Jefferies Financial Group raised their price objective on Danaher from $245.00 to $255.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Evercore ISI lifted their target price on shares of Danaher from $226.00 to $245.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Twenty-one equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $248.25.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.